Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 28, 2007

ALTEON INC.
(Exact name of registrant as specified in its charter)
         
Delaware
  
001-16043
  
13-3304550
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

221 West Grand Avenue
Montvale, New Jersey 07645
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (201) 934-5000


Not Applicable
___________________________________
Former name or former address, if changed since last report




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

ITEM 8.01 OTHER EVENTS.

On June 28, 2007, Alteon Inc. (the “Company”) announced that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications. This dose escalating study is designed to evaluate ALT-2074’s ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. 
 
(d)  Exhibits.

99.1 Press Release dated June 28, 2007.

 
2
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  ALTEON INC.
 
 		  
 		  
 
Date: June 28, 2007 By:   /s/ Noah Berkowitz, M.D. , Ph.D.
 
Noah Berkowitz, M.D., Ph.D.
  President and Chief Executive Officer


 
3
 


EXHIBIT INDEX

   
Exhibit Number Description 
   
99.1
Press Release dated June 28, 2007.


 
4